Table 2. Effects of Dabigatran and Rivaroxaban on TG in PPP (high tissue factor).
| Treatment | LT (min) | TTP (min) | PH (nM) | ETP (min x nM) |
| Control | 2.7±0.4 | 5.2±0.5 | 329.4±24.7 | 1942±152 |
| Dabi 250 nM | 5.6±1.0** | 7.7±1.1** | 313.0±30.9 | 1792±207 |
| Dabi 500 nM | 7.8±1.3*** | 9.8±1.2*** | 250.1±27.4*** | 1307±147*** |
| Dabi 1000 nM | 11.6±1.8*** | 13.8±1.7*** | 85.3±12.4*** | 574±54*** |
| Riva 250 nM | 7.9±0.5*** | 18.6±0.9*** | 89.0±3.6*** | 1616±21* |
| Riva 500 nM | 9.3±0.3*** | 22.1±1.1*** | 66.0±1.7*** | 1436±32** |
| Riva 1000 nM | 10.6±0.4*** | 25.1±1.1*** | 48.3±1.9*** | 982±44*** § |
TG, thrombin generation triggered by 5 pM recombinant tissue factor; PPP, platelet-poor plasma; Dabi, dabigatran; Riva, rivaroxaban; LT, lag time; TTP, time to peak of TG; PH, peak height of TG; ETP, endogenous thrombin generation potential.
Data are shown as the mean ± SD. * P<0.05, ** P<0.01, and *** P<0.001 vs. control.
§
indicates that, since TG curves did not come down to the baseline within 60 min, ETP values were calculated by setting the start tail at 60min.